INSM - NASDAQ
Insmed Incorporated
$103.86
+0.13%Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
At a Glance
Live Snapshotinsm
Cost of Revenue
Last Annual Value
124.88M
3-Year CAGR
31%
5-Year CAGR
26%
10-Year CAGR
51%
Insmed Incorporated Competitors Analysis of Cost of Revenue
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Insmed Incorporated NASDAQ:INSM | 124.88M | 24.0% | 23.1% | 48.2% | |
 ResMed Inc. NYSE:RMD | 2.09B | 3.8% | 9.0% | 10.5% | |
 GE HealthCare Technologies Inc. NASDAQ:GEHC | 12.38B | 2.1% | 3.5% | N/A | |
 Humana Inc. NYSE:HUM | 110.81B | 7.8% | 9.9% | N/A | |
3.31B | -0.6% | 2.6% | 5.1% | ||
 Cardinal Health, Inc. NYSE:CAH | 214.41B | 2.7% | 6.6% | 6.4% | |
 IQVIA Holdings Inc. NYSE:IQV | 12.02B | 7.3% | 5.4% | 9.7% | |
 BeOne Medicines Ltd. NASDAQ:ONC | 668.54M | 20.7% | 32.3% | 21.2% |
Insmed Incorporated Fair Value Envelope
Related Guides
Continue your INSM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.